Seeking Participants for hIBM/GNE Clinical Trial
A phase 1 trial of Ultragenyx’ treatment for hereditary inclusion-body myopathy caused by GNE mutations is taking place in New York and California
by Quest Staff on November 30, 2011 - 2:46pm
|
Update (Feb. 11, 2013): The phase 2 trial is no longer recruiting participants. Update (March 15, 2012): This phase 1 trial is no longer recruiting participants. A phase 2 trial of sialic acid extended release tablets in people with GNE-related IBM is getting under way. See Phase 2 Study of SA-ER Tablets or enter NCT01517880 in the search box at ClinicalTrials.gov. |
Ultragenyx Pharmaceutical in Novato, Calif., is developing an experimental treatment for a form of hereditary inclusion-body myopathy, or hIBM, that’s caused by mutations in the GNE gene.
This gene codes for a protein that’s needed to make sialic acid. The Ultragenyx product is an extended-release form of sialic acid.
The company announced Nov. 30, 2011, that it is seeking more participants for its phase 1 hIBM/GNE myopathy trial. Phase 1 trial sites are located in New York and California. Travel and lodging costs for participating in the trial will be covered.
Participation in the phase 1 trial does not preclude individuals from participating in later trials.
To learn more about the trial, contact one of these centers:
|
California |
New York |
 |
About Clinical Trials A clinical trial is a test, in humans, of an experimental treatment. Although it's possible that benefit may be derived from participating in a clinical trial, it's also possible that no benefit, or even harm, may occur. |
Related Articles
MDA cannot respond to questions asked in the comments field. For help with questions, contact your local MDA office or clinic or email publications@mdausa.org. See comment policy
Connect with MDA
Muscular Dystrophy Association — USA
National Headquarters
3300 E. Sunrise Drive
Tucson, AZ 85718
(800) 572-1717
©2013, Muscular Dystrophy Association Inc. All rights reserved.
